11C-choline positron emission tomography/computed tomography for detection of disease relapse in patients with history of biochemically recurrent prostate cancer and prostate-specific antigen ≤0.1 ng/ml
- 1 April 2021
- journal article
- research article
- Published by Medknow in Journal of Cancer Research and Therapeutics
- Vol. 17 (2) , 358-365
Abstract
Objectives: The objective was to evaluate the diagnostic performance of surveillance 11C-choline positron emission tomography/computed tomography (PET/CT) for the detection of disease relapse in patients with a history of biochemically recurrent (BCR) prostate cancer (PCa) and prostate-specific antigen (PSA) ≤0.1 ng/ml. Materials and Methods: We included patients who had been treated for BCR PCa and had a surveillance 11C-choline PET/CT at serum PSA ≤0.1 ng/ml. Positive surveillance PET/CT was defined as a study that identified a new tracer-avid lesion or new tracer uptake in a previously treated lesion or both. Findings were confirmed against a composite radiologic-pathologic gold standard. Time to recurrence association analyses were performed for disease relapse risk with the use of Cox proportional hazards regression. Results: In total, 13 (12.1%) of the 107 patients had positive surveillance PET/CT scans, confirmed on pathologic assessment (n = 5) and subsequent imaging (n = 8). Among these 13 patients, ten had distant metastases, two had local recurrence, and one had both. Nine of the ten patients with metastases had oligometastatic disease defined as the presence of ≤3 metastases. Serum PSA became detectable again in only seven patients with positive surveillance PET/CT, after a mean interval from surveillance PET/CT of 292 days (range: 105–543 days). We identified an association of N stage with increased risk of recurrence (hazard ratio = 3.85; P = 0.036) although this was not significant after accounting for multiple testing. Conclusions: Surveillance i 11C-choline PET/CT can detect early disease relapse at serum PSA ≤0.1 ng/ml in patients with a history of BCR PCa.Keywords
This publication has 24 references indexed in Scilit:
- Early Biochemical Relapse After Radical Prostatectomy: Which Prostate Cancer Patients May Benefit from a Restaging11C-Choline PET/CT Scan Before Salvage Radiation Therapy?Journal of Nuclear Medicine, 2014
- Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus PanelEuropean Journal of Cancer, 2014
- Small cell carcinoma of the prostateNature Reviews Urology, 2014
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate CancerEuropean Urology, 2014
- Detection of Recurrent Prostate Cancer After Radical Prostatectomy: Comparison of 11C-Choline PET/CT with Pelvic Multiparametric MR Imaging with Endorectal CoilJournal of Nuclear Medicine, 2014
- Operational Characteristics of 11 C-Choline Positron Emission Tomography/Computerized Tomography for Prostate Cancer with Biochemical Recurrence After Initial TreatmentJournal of Urology, 2013
- Imaging of Recurrent Prostate CancerRadiologic Clinics of North America, 2012
- Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate CancerJournal of Clinical Oncology, 2008
- Choline phospholipid metabolism: A target in cancer cells?Journal of Cellular Biochemistry, 2003